What is it about?
This is a prospective, longitudinal, and analytical study was conducted. Neurological, neurocognitive, and neuropsychiatric assessments of participants who had recovered from COVID-19 and did not require hospitalization during the acute stages of the infection were performed. Peripheral levels of LPS and tryptophan metabolites were measured 1, 3, 6, and 12 months after infection.
Featured Image
Why is it important?
Periodontal diseases were found among participants in the COVID-19–convalescent group compared with participants in the comparison group. A significant decrease in kynurenine levels, which correlated with cognitive impairment, was observed among PASC convalescents. Significant neurocognitive and neuropsychiatric impairments were observed among COVID-19–convalescent individuals, along with decreased kynurenine levels, which recovered during a 12-month follow-up period.
Perspectives
Although COVID-19 is generally no longer fatal for most individuals because of vaccination efforts, more people are at risk for developing PASC. Interestingly, neuropsychiatric signs and symptoms seem to be the most common among patients with long COVID. More studies to long-term follow up are required.
Graciela Cárdenas
Instituto Nacional de Neurología y Neurocirugía
Read the Original
This page is a summary of: Long-Term Neuropsychiatric Sequelae of COVID-19 in an Open Population: A Prospective Pilot Study, Journal of Neuropsychiatry, May 2025, American Psychiatric Association,
DOI: 10.1176/appi.neuropsych.20240040.
You can read the full text:
Contributors
The following have contributed to this page
